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Abstract 
Clostridium difficile is the main causative agent of antibiotic-associated diarrhea and colitis in hospitalized 
patients, the disease is caused mainly by two exotoxins, TcdA and TcdB, produced by the bacteria. Recurrent C. 
difficile infection (CDI) constitutes one of the most significant clinical issues of this disease . This study aimed 
to Determination the pathological effects of C. difficile in mice, the results shown  that bacterial dose 1x106 
CFU\ml led to 50% death within (2-4) days post infection and 100% developed diarrhea ,that would cause 
infection but not universal lethality . In conclusion, we have established a mouse  CDI model that allows for 
future investigations of the role of the host immuneresponse in the disease’s pathogenesis and permits critical 
testing of new therapeutics targeting recurrent disease. 
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Introduction 
Clostridium difficile  (C. difficile)  infections  (CDI)  are  a clinical concern  and  are   one  of  the   leading  
causes  of   antibiotic -  associated diarrhea  of   nosocomial outbreaks,    CDI   is  dramatically  increasing  in  
both  the   prevalence  and   clinical severity   of cases. (McFarland, 2015) 
C. difficile is a Gram positive, rod-shaped, sporforming, anaerobic and toxin producing bacteria, 
commonly isolated from soil, humans, and other mammals (Kuijper et al., 2006 ;McFee and  Abdelsayed , 2009) 
. Also is a multidrug-resistant pathogen, flourishes in the colon after the gut microbiota has been altered by 
antibiotic therapy (Darkoh et al.,2015). Acquired either from the environment or the fecal- oral route (Khanna et 
al.,2012;  Julia et al.,2013). About (15- 25)% of the episodes  of  antibiotic  associated  diarrhea   (AAD) is  
linked   with  the   pathogenic 
strains , also 86% of C. difficile isolates from the suspected cases of C. difficile associated diarrhea 
(CDAD) were characterized as toxigenic .(Barbut et al., 2007; Cohen et al.,2010) . The CDI were associated 
with two virulence factors potential toxins including enterotoxin A and cytotoxin B (linked to the tcdA and tcdB 
genes, respectively), producing from pathogenic strains of C. difficile (Sunenshine and McDonald , 2006 ; 
Kuehne et al., 2011 ) .Another toxin known as C. difficile binary toxin (cdt) has been isolated from some certain 
strains that associated with severe infectious form of disease in human (McEllistrem et al., 2005 ; Songer , 2010 
; Lessa et al., 2012). 
Clinically, there is a wide spectrum of C. difficile presentations ranging from asymptomatic carriage to 
severe, life threatening, fulminant colitis, and toxic megacolon (Bartlett and Cerding ,2008; Surawicz,2013).The 
severity of CDI ranges from mild diarrhea to pseudo membranous colitis (PMC) and can result in death (Alcala 
,2013), reaching (95–100)% among patients with documented antibiotic-associated colitis (Christina et al.,2013). 
Recurrent CDI occurs in more than 20% of patients (Sun  et al.,2011), that become more frequent, more severe, 
more refractory to standard treatment , and more likely to relapse (Mattila et al.,2012; Khanna and pardi , 2014) . 
The aims of this study is to Determination pathological study of C. difficile in mice. 
 
Materials and Methods 
C.difficile isolate: 
C. difficile were isolation and identification from stool samples were collected from hospital in Baghdad  
previously by :1.selective media. 2.Gram stain ,Malachite green for spore,Api20A Kit(BioMerieux,USA). 
3.detection of two toxins A&B in stool samples by ELISA Kit (primier toxin A&B from Meridian Bioscience 
,USA).4. Detection of toxins A&B genes by PCR method .(Mehdi and Al-Mossawei,2015). 
 
Preparation of  C. difficile spores : 
Five different dose of spores (1x104,1x105 ,1x106,1x107,1x108)spore \ml were used for challenge orally  to 
determined the suitable concentration that will be use to experimental study in mice ,as following:        
Concentration of spore\ml=(106 x4xB)\N 
were : B= spores number , N=chamber square counted . 
Sporulation of the C. difficile was induced on  brain heart infusion (BHIS) agar, culture were diluted in fresh 
media  to turbidty equal McFarland (0.5), 0.1ml of this suspension was spread on BHIS agar and  anaerobic 
incubation for seven days, the spores were washed off the plate with phosphate buffered saline, and stored at 4 0 
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C ,and concentration determined by serial  dilution  and using cytometer chamber and McFarland(0.5)  (Sorg et 
al.,2010). Each mouse was inoculated intragastrically by sterile 1 ml gavage syringe with 200 µl of the spore 
suspension containing (1x104,1x105,1x106,1x107,1x108)   CFU/ml (Sun et al.,2011)  for challenge . 
 
Experimental infection in mice : 
Thirty six(n=36) albino male mice, Mus musculus BALB /C strain aged (5-6 )weeks and weighing (20-25) g. 
were obtained from AL-Nahrain research center  ,AL-Nahrain university. 
 
Determination the pathogenicity of C.difficile isolates  among mice: 
Thirty six(n=36) mice were randomly divided into six  groups designated as 1, 2, 3,4,5 and 6. Each group 
consisted of 6 mice, and subjected to the following treatments according to(Sun et al.,2011). Scheme(1). 
To establish C.difficile ,mice were treated at day (0-3) with an antibiotic  mixture   in drinking  water:  
Clindamycin( 0.1mg\ml\Pharma ,USA)  , 
Metronidazol(0.215mg\ml\India),Vancomycin(0.045mg\ml\Julphar,U.A.E), followed, at day 4 
,administration 200µl of Clindamycin concentration (0.2mg\ml) orally, and at day 5, administration 500µl of 
Clindamycin concentration (0.2mg\ml)  intraperitoneal injection (i.p.) .(Chen et al.,2008) . These drugs that have 
been used to disrupt intestinal microbial to establish of C.difficile  infection. 
 
Scheme(1) Experimental study of C.difficile Pathogenicity among mice. 
 
Results and Discussion 
Pathogenicity of C.difficile among mice : results shown  in table (1)bacteria dose of 1x106 CFU\ml led to 50% 
death within (2-4) days post infection and 100% developed diarrhea ,that would cause infection but not universal 
lethality .figure (1) that was selected as suitable dose . 
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Table( 1):The suitable bacteria dose concentration CFU\ml  that would cause severe infection in experimental 
mice ( each group No =6) 
Bacterial Dose 
CFU\ml 
Total No .of 
mice in each 
group 
Death of mice No. 
within (2-4) day post 
infection(%) 
No. of Developed 
diarrhea(%) 
Chi- square(χ2) 
1x104 6 0 (0.00%) 2 (33.33%) 9.715 ** 
1x105 6 2 (33.33%) 4 (66.67%) 9.715 ** 
1x106 6 3 (50.00%) 6 (100%) 11.569 ** 
1x107 6 5 (83.33%) 6 (100%) 6.723 ** 
1x108 6 6 (100%) 6 (100%) 0.00 NS 
Chi- square(χ2)  15.248 ** 11.804 ** --- 
 ** (P<0.01), NS: Non-significant. 
There were highly   significant   differences between each concentration groups . 
C. difficile is responsible of AAD in humans and   animals,    and is one of the most 
common nosocomial pathogens. Pathogenic C. difficile produces two exotoxins, toxin A and toxin B which 
induce intestinal inflammation, fluid secretion and mucosal injury (Pothoulakis, 1996). 
In conclusion, we have established a mouse  CDI model that allows for future investigations of the role of the 
host immuneresponse in the disease’s pathogenesis and permits critical testing of new therapeutics targeting 
recurrent disease. 
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figure (1):suitable bacterial dose 106 CFU \ml 
concentrate that would  cause 100% sever infection .
Death within (2-4) day post
infection
Developed diarrhea
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